DOR BioPharma, Inc. Reports Second Quarter 2006 Financial Results and Reviews Achievements (RedNova)
DOR BioPharma, Inc. (OTCBB:DORB) ("DOR" or the "Company"), announced today its financial results for the second quarter ended June 30, 2006. Revenue for the second quarter of 2006 was approximately $0.1 million, compared to $1.4 million in the second quarter of 2005.

Amarillo Biosciences IND Application Passes FDA Review (SYS-CON Media)
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR), today announced that the Company's Investigational New Drugapplication (IND) for idiopathic pulmonary fibrosis (IPF) has successfullypassed the FDA's 30-day review process and has been allowed to go intoeffect. A Phase II, 60-patient study to test low dose oral interferon as atreatment of chronic cough in IPF patients is on target to launch in